prod:prod_dcx-login
Xpert® vanA
Rapid VRE screening for active outbreak prevention and control in around 48 minutes
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
10 Tests
GXVANA-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Collection devices
Collection Device (Pack of 50)
900-0370
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support
The Need
- Vancomycin Resistant Enterococci (VRE) are a growing public health threat and pose a risk to patient safety in healthcare facilities1
- In healthcare settings, colonized patients and environmental contamination contribute to VRE spread1
- High-risk patients colonized with VRE have 24 times increased infection risk2
- Infections caused by VRE are associated with high mortality3
- VRE has an impact on patient length-of-stay, and in turn, hospitalization costs3
1 Levitus M, et al. Vancomycin-Resistant Enterococci. StatPearls July 17, 2023. https://www.ncbi.nlm.nih.gov/books/NBK513233/?report=reader#_NBK513233_pubdet. Accessed December 11, 2023
2 Alevizakos M, et al. Colonization with vancomycin-resistant enterococci and risk for bloodstream infection among patients with malignancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2016 Dec;4(1):ofw246.
3 Eichel V,M, et al. Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis. Journal of Hospital Infection 141 (2023) 119e128
2 Alevizakos M, et al. Colonization with vancomycin-resistant enterococci and risk for bloodstream infection among patients with malignancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2016 Dec;4(1):ofw246.
3 Eichel V,M, et al. Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis. Journal of Hospital Infection 141 (2023) 119e128
The Solution
- The Xpert vanA test is a rapid and accurate method for detection of VRE colonization among high-risk admissions and for screening during outbreaks of VRE
- Fast, active screening of high-risk patients to prevent the spread of VRE and better manage colonized and infected patients4
4 Babady N,E, et al. Performance Characteristics of the Cepheid Xpert vanA Assay for Rapid Identification of Patients at High Risk for Carriage of Vancomycin-Resistant Enterococci. Journal of Clinical Microbiology, November 2012 Volume 50 Number 11 p. 3659–3663
The Impact
Rapid PCR results facilitate more efficient infection control surveillance programs5
- 93% reduction of turnaround time from 70.5h with chromogenic agar culture to 4.6h
- High negative predictive value allows for better management of non-colonized patients
- Decreased the number of contact patients thereby preventing VRE transmission
- 94% reduction in overall cost ($15,645 with culture vs $952*)
- 141 saved isolation days and 292 saved transmission risk days
5 Birgand G, et al. Lucet JC. Rapid detection of glycopeptide-resistant enterococci: impact on decision-making and costs. Antimicrobial Resistant and Infection Control. 2013 Nov 2:30.
6 Holzknecht BJ, Hansen DS, Nielsen L, Kailow A, Jarløv JO. Screening for vancomycin-resistant enterococci with Xpert® vanA/vanB: diagnostic accuracy and impact on infection control decision making. New Microbes New Infect. 2017 Jan 12;16:54-59
* 1€=1.09$, conversion rate December 15th 2023
6 Holzknecht BJ, Hansen DS, Nielsen L, Kailow A, Jarløv JO. Screening for vancomycin-resistant enterococci with Xpert® vanA/vanB: diagnostic accuracy and impact on infection control decision making. New Microbes New Infect. 2017 Jan 12;16:54-59
* 1€=1.09$, conversion rate December 15th 2023
Related Products
Xpert Norovirus
Fast and accurate identification of Norovirus GI & GII in as little as one hour* *With early assay termination for positive results. Reporting negative results in 90 minutes.
Xpert MRSA/SA Blood Culture
Accurate Detection of MRSA and SA in Positive Blood Culture Specimens in About an Hour
Xpert MRSA NxG
Active MRSA surveillance testing in around 70 minutes
Xpert C. difficile
Detection of toxigenic C. difficile in around 43 minutes
Xpert Carba-R
Detection and differentiation of KPC, NDM, VIM, IMP-1, and OXA-48 in 50 minutes
Xpert MRSA/SA SSTI
Detect MRSA & SA Skin and Soft Tissue Infections In About One Hour
Xpert SA Nasal Complete
Pre-surgical S. aureus and MRSA in about 65 minutes
Xpert C. difficile/Epi
Detection of Clostridium difficile infection with an independent call-out of the 027 strain in around 45 minutes